5 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 23 points (-0.2%) at 15,311 as of Wednesday, Sept. 25, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,760 issues advancing vs. 1,167 declining with 109 unchanged.

The Health Care sector currently sits up 0.9% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the sector include Baxter International ( BAX), down 5.6%, Stryker Corporation ( SYK), down 2.1%, Zimmer Holdings ( ZMH), down 1.3%, WellPoint ( WLP), down 0.9% and Novo Nordisk A/S ( NVO), down 1.0%.

TheStreet would like to highlight 5 stocks pushing the sector lower today:

5. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.24 (-0.6%) to $38.48 on light volume. Thus far, 1.2 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $38.16-$38.87 after having opened the day at $38.77 as compared to the previous trading day's close of $38.72.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $32.1 billion and is part of the drugs industry. Shares are up 1.8% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 14 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.73 (-0.8%) to $92.09 on light volume. Thus far, 421,409 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $91.96-$92.92 after having opened the day at $92.92 as compared to the previous trading day's close of $92.82.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $33.6 billion and is part of the health services industry. Shares are up 46.3% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Medtronic ( MDT) is down $0.29 (-0.5%) to $53.14 on light volume. Thus far, 1.1 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $52.95-$53.48 after having opened the day at $53.46 as compared to the previous trading day's close of $53.43.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. The company operates in two segments, Cardiac and Vascular Group, and Restorative Therapies Group. Medtronic has a market cap of $53.6 billion and is part of the health services industry. Shares are up 31.1% year to date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Medtronic a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Medtronic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.08 (-0.2%) to $46.74 on light volume. Thus far, 1.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $46.41-$46.89 after having opened the day at $46.75 as compared to the previous trading day's close of $46.82.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $76.6 billion and is part of the drugs industry. Shares are up 42.8% year to date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.39 (-1.2%) to $113.39 on light volume. Thus far, 1.2 million shares of Amgen exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $112.52-$114.80 after having opened the day at $114.80 as compared to the previous trading day's close of $114.78.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $86.7 billion and is part of the drugs industry. Shares are up 33.5% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)